International Journal of Clinical Research

Objective To analyze and discuss the clinical efficacy of ezetimibe combined with rosuvastatin in the treatment of patients with high cholesterol and cardiovascular risk. Methods 100 patients with high cholesterol and cardiovascular risk admitted to our hospital from January 2022 to January 2023 were selected as the research subjects. They were evenly divided into an observation group (treated with ezetimibe combined with rosuvastatin) and a control group (treated with ezetimibe). The carotid atherosclerosis, plasma lipoprotein related phospholipase A2, and blood lipid levels before and after treatment were compared between the two groups, as well as the treatment effect. Results After treatment, the Crouse score and carotid intima-media thickness (3.05 ± 0.32 points, 0.89 ± 0.51mm) of the observation group were lower than those of the control group, and the carotid artery diameter (7.89 ± 1.54mm) was higher than that of the control group (P<0.05); 2. After treatment, the plasma lipoprotein related phospholipase A2 index and blood lipids in the observation group (163.12 ± 12.59 μ g/L, 1.72 ± 0.32mmol/L, 1.67 ± 0.14mmol/L, 4.02 ± 0.95mmol/L, 1.05 ± 0.28mmol/L) were better than those in the control group (P<0.05); The treatment effect of the observation group (94.0%) was higher than that of the control group, (P<0.05). Conclusion The combination of ezetimibe and rosuvastatin is effective in the treatment of patients with high cholesterol and cardiovascular risk, and is worthy of wide promotion and application.

Yizhemai Bu; Rosuvastatin; Hypercholesterolemia; High cardiovascular risk; Clinical efficacy